Key opportunities in the oligonucleotide market include advancing therapeutics for rare and diverse diseases like neurodegenerative disorders and cancer, improving drug delivery systems, leveraging ...

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant ...

View Sagimet Biosciences Inc. Class A SGMT stock quote prices, financial information, real-time forecasts, and company news from CNN.

View Pharming Group NV Sponsored ADR PHAR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Korro Bio Inc. company and executive profile by Barron's. View the latest KRRO company infomation and executive bios.

Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio today and set a price target of $30.00.

Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to a loss of $2.26 per share a year ago. These figures ...

Fintel reports that on February 17, 2026, William Blair upgraded their outlook for Korro Bio (NasdaqCM:KRRO) from Market Perform to Outperform. As of February 4, 2026, the average one-year price ...

Korro Bio, Inc. (NASDAQ:KRRO) is next on our list of best biotech stocks. TheFly reported on January 29 that H.C. Wainwright upgraded KRRO from Neutral to Buy with a $20 price target. The firm ...

Fintel reports that on January 29, 2026, Chardan Capital upgraded their outlook for Korro Bio (NasdaqCM:KRRO) from Neutral to Buy. Analyst Price Forecast Suggests 292.64% Upside As of January 14, 2026 ...